Article
Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.
Digestive diseases and sciences - 1 Nov 2011
Amanzada Ahmad, Goralczyk Armin, Moriconi Federico, Blaschke Martina, Schaefer Inga-Marie, van Thiel David, Mihm Sabine, Ramadori Giuliano
Abstract excerpt
BACKGROUND AND AIMS: The standard treatment regimen for chronic HCV genotype 3 (HCV-G3) hepatitis consists of PEGylated interferon-α (IFN-α) and ribavirin at varying doses ranging from 400 to 1,200 mg and results in response rates of 80%. However, this therapy has substantial side-effects includi...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.